Summit Financial LLC decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 5.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 20,304 shares of the company’s stock after selling 1,233 shares during the period. Summit Financial LLC’s holdings in Johnson & Johnson were worth $3,182,000 as of its most recent SEC filing.
A number of other hedge funds have also recently made changes to their positions in the stock. International Assets Investment Management LLC lifted its stake in Johnson & Johnson by 7,875.8% during the 4th quarter. International Assets Investment Management LLC now owns 2,090,384 shares of the company’s stock valued at $327,647,000 after acquiring an additional 2,064,175 shares during the period. LSV Asset Management grew its position in Johnson & Johnson by 89.9% in the 3rd quarter. LSV Asset Management now owns 2,251,770 shares of the company’s stock worth $350,713,000 after purchasing an additional 1,065,880 shares during the period. abrdn plc boosted its stake in shares of Johnson & Johnson by 104.1% in the 4th quarter. abrdn plc now owns 2,014,743 shares of the company’s stock worth $315,791,000 after buying an additional 1,027,441 shares during the last quarter. Commerzbank Aktiengesellschaft FI grew its holdings in shares of Johnson & Johnson by 2,264.8% in the third quarter. Commerzbank Aktiengesellschaft FI now owns 822,725 shares of the company’s stock worth $128,139,000 after acquiring an additional 787,934 shares during the period. Finally, Envestnet Asset Management Inc. lifted its holdings in Johnson & Johnson by 22.2% in the third quarter. Envestnet Asset Management Inc. now owns 3,957,429 shares of the company’s stock valued at $616,370,000 after acquiring an additional 719,472 shares during the period. 69.55% of the stock is owned by institutional investors.
Johnson & Johnson Trading Down 0.5 %
Shares of JNJ stock opened at $148.57 on Tuesday. The company has a market cap of $357.56 billion, a PE ratio of 9.26, a price-to-earnings-growth ratio of 2.46 and a beta of 0.55. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94. The stock’s 50 day simple moving average is $153.95 and its two-hundred day simple moving average is $155.00. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $175.97.
Johnson & Johnson Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st will be given a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.34%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date of this dividend is Monday, May 20th. Johnson & Johnson’s payout ratio is 29.68%.
Insider Transactions at Johnson & Johnson
In related news, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the transaction, the insider now owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the sale, the insider now directly owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the sale, the executive vice president now owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.
Analyst Ratings Changes
JNJ has been the subject of a number of research reports. HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and upped their target price for the company from $169.00 to $170.00 in a report on Thursday, April 18th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a report on Monday. Bank of America decreased their price objective on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. Royal Bank of Canada dropped their target price on shares of Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating for the company in a report on Wednesday, April 17th. Finally, StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Seven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $175.86.
View Our Latest Research Report on Johnson & Johnson
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Recommended Stories
- Five stocks we like better than Johnson & Johnson
- How Investors Can Find the Best Cheap Dividend Stocks
- 3 CEO-Led Turnaround Stocks You Can Still Buy
- Dividend Capture Strategy: What You Need to Know
- 3 Value Stocks You Can Buy Before They Become Big
- Upcoming IPO Stock Lockup Period, Explained
- Chinese Stocks Stage Impressive Rebound
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.